GSK's Nucala Shows Promise In A Rare Systemic Vasculitis
GlaxoSmithKline is cementing its leadership position in eosinophilic conditions with promising pivotal results with Nucala as an add-on therapy for the rare disorder eosinophilic granulomatosis with polyangiitis. The development is expected to lead to an extension of its indications.
You may also be interested in...
NICE Gives Nucala Initial OK In Severe Asthma After GSK Offers Price Cut
Adult patients with severe eosinophilic asthma in England and Wales look set to get a much needed treatment option following NICE's provisional backing of GlaxoSmithKline's new MAb therapy.
Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy
Chiesi may be coming late to the development of eosinophilic asthma therapies, but there are certain advantages associated with acquisition target Atopix Therapeutics’ potential products that could strengthen the specialty pharma's already significant presence in the asthma market.
Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market
AstraZeneca hopes its investigative biologic benralizumab has strongly differentiated itself from rival therapies Nucala and Cinqair with the detailed publication of Phase III data showing it significantly cut exacerbations and improved lung function and symptoms in patients with severe eosinophilic asthma, as well as offering a favorable dosing schedule.